Overview

Anadys Pharmaceuticals Inc. is a drug discovery company focused on the translation of genomic information into small molecules. The company uses technologies in microbial genomics (GATE); affinity-based compound screening against targets of both known and unknown function (ATLAS); high-output medicinal chemistry; and cheminformatics, including proprietary software (PROTOS) to develop a portfolio of anti-infective products.

Anadys, which is derived from the Greek words meaning “East-to-West,” has developed Riboproteomics, a technology that identifies and maps protein-RNA interactions. RNA has been validated as a target for the treatment of infectious diseases with approved drugs, such as neomycin and tobramycin. Anadys’ pipeline includes RNA-specific targets and compounds that bind to RNA, antibacterial and antiviral discovery programs, and anti-infective preclinical development candidates.

These enabling technologies support a number of ongoing discovery and development programs in hepatitis C virus and several antibacterial targets.

Partners

Drug Discovery: Aventis Pharma SA, Eli Lilly and Co. and Pharmacia Corp.

Strategic Alliances and Collaborations: The European Molecular Biology Laboratory.